Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Oncodesign’s kinase inhibitor library currently contains over 8,000 macrocycles. These type I kinase inhibitors, profiled using the human kinome, are potent, highly selective, and have good cell penetration. They also have good criteria in terms of developability, physicochemical properties and eADMET, with a highly predictable SAR.
Several leads are currently being optimized, both for known kinases and for unexplored kinases; they will become tomorrow’s targeted therapies in precision medicine.
The probe-based drug discovery approach helps identify « First in Class » opportunities for little explored or unexplored kinases, and our molecular diversity screening approach for kinases of interest paves the way for potential best-in-class next-generation inhibitors..